Celldex’s CSU, PN trials represent not only strong datasets but suggest barzolvolimab’s ‘pipeline-in-a-product potential’ in other mast cell-driven diseases.
Asthma-focused Aiolos Bio takes aim at Tezspire, launches with $245M raise
The acquisition will help boost Alfasigma’s gastroenterology and hepatology pipeline, all while giving it access to Intercept’s lead candidate Ocaliva.
Takeda places $580M bet on AcuraStem’s ALS treatments
The ALS program deal could be worth nearly $600 million in upfront and milestone payments for AcuraStem if all clinical, regulatory and commercial milestones are achieved.
Novo Nordisk adds another obesity biotech in potential $500 deal
The transaction, worth about $16 million upfront and up to $500 million in upcoming milestones, builds upon Novo Nordisk’s collaboration with Embark Laboratories from 2018.
Former Commerce Secretary Wilbur Ross’ SPAC scraps merger with Aprinoia Therapeutics